Finance
Novo Nordisk Faces Rare Analyst Downgrade After Clinical Setback Against Rival
A prominent sell-side analyst has downgraded Novo Nordisk for the first time in five years, citing a study where a new pipeline drug failed to outperform a competitor's offering. The move signals a potential shift in the competitive landscape for the high-stakes weight-loss and diabetes medication market.
February 24, 20261.1K views
Score-1
Enjoyed this story? Share it! 👇
Advertisement
Related Stories
Finance
Stellantis Records First Annual Loss in History Following 20 Billion Euro EV Writedown
1d ago
Finance
Imperial Petroleum Accelerates Fleet Expansion as Valuation Multiples Lag Behind Earnings
1d ago
Finance
Syngenta Prepares $10 Billion Hong Kong IPO for Second Quarter Launch
1d ago
Finance
Uber and Lyft Shares Surge as Trump Administration Scraps Independent Contractor Rule
1d ago
Comments (0)
Sign in to leave a comment.
No comments yet. Be the first to share your thoughts!